1. Home
  2. DBX vs PTCT Comparison

DBX vs PTCT Comparison

Compare DBX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dropbox Inc.

DBX

Dropbox Inc.

HOLD

Current Price

$25.45

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$65.00

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBX
PTCT
Founded
2007
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.7B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
DBX
PTCT
Price
$25.45
$65.00
Analyst Decision
Hold
Buy
Analyst Count
8
17
Target Price
$28.14
$80.65
AVG Volume (30 Days)
3.1M
966.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
32.86
264.48
EPS
1.86
7.78
Revenue
N/A
$264,734,000.00
Revenue This Year
$0.20
N/A
Revenue Next Year
N/A
$17.70
P/E Ratio
$13.47
$8.43
Revenue Growth
N/A
36.19
52 Week Low
$21.70
$37.94
52 Week High
$32.40
$87.50

Technical Indicators

Market Signals
Indicator
DBX
PTCT
Relative Strength Index (RSI) 64.84 39.37
Support Level $23.56 $62.72
Resistance Level $26.81 $69.23
Average True Range (ATR) 0.67 2.90
MACD 0.20 -0.74
Stochastic Oscillator 88.81 15.76

Price Performance

Historical Comparison
DBX
PTCT

About DBX Dropbox Inc.

Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: